Chinese Academy of Sciences

Shanghai Fochon Pharmaceutical Co., Ltd.

Shanghai Haihe Pharmaceutical Co., Ltd.

Jinan University

Haihe Biopharma Co., Ltd.

Xia Peng

Hongbin Liu

Meiyu Geng

Jing Ai

Jian Ding

Yinchun Ji

Jian Li

Yang Liu

Zhang Zhang

Weibo Wang

Xingdong Zhao

Jingkang Shen

Haohan Tan

Weipeng Zhang

Ling Chen

Qiang Tian

Xin Wang

Qi Rong Wang

Jia Tao Li

Hualiang Jiang

Takuya Matsumoto

Kaixian Chen

Ke Ding

Zhengchao Tu

Bing Xiong

Tao Meng

Ao Zhang

Lanping Ma

Youhong Hu

Zilan Song

Xiaomei Ren

Xiaoyun Lu

Li Tan

Li Xing

Danqi Chen

Wenhu Duan

Yi Zang

Yu Zhou

Hong Liu

Yang Dai

Qian Tan

Limin Zeng

Wangting Gu

Guogang Xie

Feifei Fang

Hefeng Zhang

Yuelei Chen

Wenming Ren

Xiaocong Guan

Lang Wang

Jing Al

Ying Dong

Yuchi Ma

Shingpan Chan

Qi Wang

Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.

Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof

A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof are provided. Specifically, provided herein are a compound having the structure represented by formula (I), a preparation method therefor and an application thereof in the preparation of a medication for the treatment and/or prevention of tumor-associated diseases and/or kinase-related diseases.

Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof

Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.

Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof

Provided are an exosome preparation formed by secretion by a mast cell cultured in vitro, a preparation method of an exosome therein, an exosome containing Fc&#x3b5;RI protein on an outer surface thereof and in a substantially unbound state, and uses of the exosome preparation or exosome in a method for inhibiting mast cell activation in vitro and in preparing a drug for treating an IgE-mediated disease.

Exosome preparation for treating disease and application thereof

The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof. 

Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof

An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses. 

O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumors associated with abnormal protein tyrosine kinase. 

Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof

Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Certain protein kinase inhibitors

Growing community of inventors

Shanghai, China

Xia Peng